摘要
目的:研究利奈唑胺与万古霉素治疗耐甲氧西林金黄色葡萄球菌(Methicillin-resistant staphylococcus aureus,MRSA)肺炎的临床疗效。方法:选取2010年10月至2013年10月在我院就诊的60例MRSA肺炎患者的临床资料进行分析,根据治疗方法的不同,将所选病例分为利奈唑胺组和万古霉素组。统计并分析两组患者的临床疗效、细菌学疗效以及炎症因子水平的变化情况,并对两种药物的安全性进行评价。结果:利奈唑胺组治疗有效率为83.33%,致病菌清除率为86.67%,不良反应发生率为9.52%;万古霉素组治疗有效率为86.67%,致病菌清除率为84.33%,不良反应发生率为16.00%;但两组比较差异无统计学意义(P>0.05)。两组患者治疗后血清中CRP、TNF-α水平较治疗前明显降低,利奈唑胺组下降幅度明显高于万古霉素组,差异具有统计学意义(P<0.05)。结论:两种药物治疗老年MRSA肺炎的疗效差异性不大,但利奈唑胺整体优于万古霉素。
Objective： To study the effects of linezolid and vancomycin in treatment of senile pneumonia of MRSA. Methods： Medical records of 60 senile MRSA pneumonia patients from October 2010 to 2013 in our hospital were collected and divided into line- zolid group and vancomycin group, according to different treatments. The clinical efficacy, bacteriological effect, changes of inflamma- tion factors, and safety evaluation of two groups were compared. Results： After a course of treatment, the effective rate oflinezolid group was 83.33 %, higher than 86.67 % in the vancomycin group with no significant difference （P〉0.05）. The pathogen removal efficiency of linezolid group was 86.67 %, was higher than 84.33 % in the vaneomycin group with no significant difference （P〉0.05）. Serum CRP, TNF-α levels showed no significant difference between two groups of patients before treatment （P〉0.05）. After a course of treatment, CRP, TNF-α levels of two groups were significantly lower than that before treatment （P〈0.05）, and CRP, TNF-α level of linezolid group were decreased significantly than that in vancomycin group （P〈0.05）. The adverse reaction incidence rate of linezolid group was 9.52 %, was lower than 16 % in vancomycin group, but no significant difference between the two groups （P〉0.05）. Conclusions： The cu- rative effect of linezolid and vancomycin in the treatment of elderly MRSA pneumonia is similar, but overall linezolid is better than van-comycin.
出处
《现代生物医学进展》
CAS
2015年第21期4060-4062,4028,共4页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(30670935)
